



Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
(617) 252-7570

Fast Facts About Genzyme Corporation

Founded:	1981
2008 Revenues:	\$4.6 billion
CEO:	Henri A. Termeer President 1983, CEO 1985, Chairman 1988
2008 R&D Spending:	\$750 million
Employees Worldwide:	More than 11,000
Headquarters:	Cambridge, MA
Exchange and Symbol:	Nasdaq, GENZ
Areas of Focus:	Genetic Diseases, Cardiometabolic & Renal, Hematologic Oncology, Biosurgery, Transplant, Genetics/Diagnostics

Top Products, based on FY 2008 Revenue:

Product Name	Disease/Condition	Revenue 2008
Cerezyme® (imiglucerase for injection)	Gaucher disease	\$1.2 billion
Sevelamer	renal disease	\$678 million
Fabrazyme® (agalsidase beta)	Fabry disease	\$494 million
Synvisc® (hylan G-F 20)	osteoarthritis of the knee	\$263 million

Key Pipeline Products:

Product Name	Disease/Condition
alemtuzumab	multiple sclerosis
mipomersen	high-risk hypercholesterolemia
Genz-112638 oral therapy	Gaucher disease

International Presence:

Genzyme has more than 85 locations in over 40 countries, including 17 manufacturing facilities and 9 genetic testing laboratories; the company's products are available in 100 countries.

Charitable Contributions, FY 2008:

Global product donations, \$144 million; U.S. cash contributions, \$15.5 million.